Acromegaly Market Report 2025: Insights, Epidemiology, And Industry Forecast To 2034

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Acromegaly - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Highlights

• The Acromegaly market size in the 7MM was valued at approximately USD 1.30 billion in 2023.
• Somatostatin therapies generated the highest market revenue in 2023, at about USD 300 million, with growth hormone antagonists coming in at USD 90 million in EU4 and the UK.
• The US accounted for around 55% of the total market value in 7MM.
• Diagnosis in 2023 revealed 60,000 prevalent cases in the 7MM.
• Notable companies like Crinetics Pharmaceuticals and Camurus AB are leading in developing new treatments.
• Significant gender disparity exists, with females representing about 14,000 of diagnosed cases in 2023.

Acromegaly Market Report Summary

• The report covers epidemiology segments and future growth forecasts, offering comprehensive understanding of potential market developments.
• Comprehensive analysis of current treatments and emerging therapies is discussed, including late-stage Phase III and II trials.
• A detailed market size examination from 2020 to 2034 is presented, including projections for drugs in the 7MM region.
• Qualitative insights through SWOT analysis offer a strategic advantage in business planning.

Acromegaly Market

• The US market size reached approximately USD 700 million in 2023, driven primarily by somatostatin therapy.
• Paltusotine, an emerging therapy, is expected to lead market size growth by 2034 in the 7MM region.
• The UK topped the EU4 and UK market, comprising 30% of regional market size.

Acromegaly Drug Chapters

In-depth evaluations of pipeline drugs, clinical trials, and their potential impacts on the treatment landscape are explored. Updates from companies like Amryt Pharma and Recordati provide insights into their advancements.

Marketed Acromegaly Therapies

• MYCAPSSA (octreotide acetate): Amryt Pharma/Chiasma - An oral somatostatin analog for long-term maintenance in acromegaly.
• SIGNIFOR LAR (pasireotide): Recordati/Novartis Pharmaceuticals - An injectable somatostatin analog designed for hormone normalization.

Emerging Acromegaly Therapies

• Paltusotine (CRN 00808): Crinetics Pharmaceuticals - Targeted for FDA submission in 2024, shows promise as a potent systemic therapy.
• CAM2029 (octreotide subcutaneous depot): Camurus AB - Innovatively designed for ease of use, currently in Phase III trials for acromegaly and neuroendocrine tumors.

Acromegaly Market Outlook

The landscape is dominated by surgery, medical treatments, and radiation. New treatment developments focus on novel mechanism approaches to significantly address unmet needs and drive growth from 2024 to 2034.

Acromegaly Understanding and Treatment

Acromegaly is caused by excessive hormone release, typically from a benign pituitary tumor. Standard treatment aims to control symptoms and tumor size. New medications are evolving rapidly, with therapies targeted at earlier and more effective intervention.

Acromegaly Epidemiology

• Approximately 27,000 diagnosed cases in the US by 2023, followed by Japan with 9,000 cases.
• Significant cases in US are macroadenomas, accounting for 75% versus 25% microadenomas.

Acromegaly KOL Views

Interviews with KOLs provide thorough industry insights, guiding strategic adaptation to dynamic market trends.

Qualitative Analysis

Our SWOT and conjoint analyses help navigate the strengths and weaknesses, offering clear strategic direction for industry stakeholders.

Acromegaly Market Access and Reimbursement

Detailed analysis on market accessibility, cost dynamics, and reimbursement policies ensures a strategic approach for new drugs entering the market.

Acromegaly Market Report Insights

• Detailed patient population statistics and therapeutic approaches are outlined.
• Key insights into market size, trends, and opportunities provide a roadmap for business strategy.

Acromegaly Market Report Key Strengths

• Eleven-year forecast and comprehensive 7MM analysis.
• Detailed epidemiology segmentation and competitive landscape review.

Acromegaly Market Report Assessment

• Current treatments, reimbursement challenges, and market attractiveness evaluated.
• Qualitative analysis identifying key unmet needs and therapeutic opportunities.

Key Questions Answered

• How might treatment approaches evolve with new therapies?
• How will research advances influence future tests and therapies?
• What uptake is expected for new acromegaly therapies?

Key Topics Covered

1 Key Insights
2 Report Introduction
3 Acromegaly Market Overview at a Glance
4 Executive Summary of Acromegaly
5 Key events
6 Disease Background and Overview
7 Methodology
8 Acromegaly Epidemiology and Patient Population
9 Acromegaly Patient Journey
10 Acromegaly Marketed Therapies
11 Emerging Acromegaly Therapies
12 Acromegaly Market: Seven Major Market Analysis
13 Acromegaly KOL Views
14 Acromegaly SWOT Analysis
15 Acromegaly Unmet Needs
16 Acromegaly Market Access and Reimbursement
17 Appendix

A selection of companies mentioned in this report includes, but is not limited to:

• Crinetics Pharmaceuticals
• Camurus AB

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN08052025004107003653ID1109522971